{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-237832","form_type":"8-K","ticker":"OLMA","cik":"0001750284","company_name":"Olema Pharmaceuticals, Inc.","filed_at":"2026-05-26T11:05:16+00:00","discovered_at":"2026-05-26T11:10:00.237897+00:00","generated_at":"2026-05-26T11:14:23.093292+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"confidence":"high","headline":"Olema partners with Bayer for OP-3136 + darolutamide Phase 1b/2 in mCRPC; 36 patients, H2 2026 start","bullets":["Olema and Bayer will evaluate OP-3136 (KAT6 inhibitor) combined with darolutamide in ~36 mCRPC patients.","Phase 1b/2 study expected to initiate in second half of 2026; Bayer supplies darolutamide.","Olema retains full global commercial and marketing rights to OP-3136; clinical data and inventions jointly owned.","First clinical collaboration for OP-3136; builds on ongoing Phase 1/2 monotherapy and combination studies.","Olema to present initial Phase 1 OP-3136 monotherapy data at ASCO on May 30, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-237832","json":"https://secwatch.observer/filing/0001193125-26-237832.json","markdown":"https://secwatch.observer/filing/0001193125-26-237832.md","text":"https://secwatch.observer/filing/0001193125-26-237832.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750284/000119312526237832/0001193125-26-237832-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750284/000119312526237832/olma-20260526.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T11:14:23.093292+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}